Background & Aims: Autoimmune hepatitis (AIH) has been well characterised and codified through the development of diagnostic criteria. These criteria have been adapted and simplified and are widely used in clinical practice. However, there is a need to update and precisely define the criteria for both treatment response and treatment. Methods: A systematic review was performed and a modified Delphi consensus process was used to identify and redefine the response criteria in autoimmune hepatitis. Results: The consensus process initiated by the International Autoimmune Hepatitis Group proposes that the term ‘complete biochemical response’ defined as ‘normalization of serum transaminases and IgG below the upper limit of normal’ be adopted to include a time point at 6 months after initiation of treatment. An insufficient response by 6 months was a failure to meet the above definition. Non-response was defined as ‘<50% decrease of serum transaminases within 4 weeks after initiation of treatment’. Remission is defined as liver histology with a Hepatitis Activity Index <4/18. Intolerance to treatment was agreed to stand for ‘any adverse event possibly related to treatment leading to potential drug discontinuation’. Conclusions: These definitions provide a simple and reproducible framework to define treatment response and non-response, irrespective of the therapeutic intervention. A consensus on endpoints is urgently required to set a global standard for the reporting of study results and to enable inter-study comparisons. Future prospective database studies are needed to validate these endpoints. Lay summary: Consensus among international experts on response criteria and endpoints in autoimmune hepatitis is lacking. A consensus on endpoints is urgently required to set a global standard for the reporting of study results and to enable the comparison of results between clinical trials. Therefore, the International Autoimmune Hepatitis Group (IAIHG) herein presents a statement on 5 agreed response criteria and endpoints: complete biochemical response, insufficient response, non-response, remission, and intolerance to treatment, which can be used to guide future reporting.

Pape, S., Snijders, R., Gevers, T., Chazouilleres, O., Dalekos, G., Hirschfield, G., et al. (2022). Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. JOURNAL OF HEPATOLOGY, 76(4 (April 2022)), 841-849 [10.1016/j.jhep.2021.12.041].

Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

Gerussi A.;
2022

Abstract

Background & Aims: Autoimmune hepatitis (AIH) has been well characterised and codified through the development of diagnostic criteria. These criteria have been adapted and simplified and are widely used in clinical practice. However, there is a need to update and precisely define the criteria for both treatment response and treatment. Methods: A systematic review was performed and a modified Delphi consensus process was used to identify and redefine the response criteria in autoimmune hepatitis. Results: The consensus process initiated by the International Autoimmune Hepatitis Group proposes that the term ‘complete biochemical response’ defined as ‘normalization of serum transaminases and IgG below the upper limit of normal’ be adopted to include a time point at 6 months after initiation of treatment. An insufficient response by 6 months was a failure to meet the above definition. Non-response was defined as ‘<50% decrease of serum transaminases within 4 weeks after initiation of treatment’. Remission is defined as liver histology with a Hepatitis Activity Index <4/18. Intolerance to treatment was agreed to stand for ‘any adverse event possibly related to treatment leading to potential drug discontinuation’. Conclusions: These definitions provide a simple and reproducible framework to define treatment response and non-response, irrespective of the therapeutic intervention. A consensus on endpoints is urgently required to set a global standard for the reporting of study results and to enable inter-study comparisons. Future prospective database studies are needed to validate these endpoints. Lay summary: Consensus among international experts on response criteria and endpoints in autoimmune hepatitis is lacking. A consensus on endpoints is urgently required to set a global standard for the reporting of study results and to enable the comparison of results between clinical trials. Therefore, the International Autoimmune Hepatitis Group (IAIHG) herein presents a statement on 5 agreed response criteria and endpoints: complete biochemical response, insufficient response, non-response, remission, and intolerance to treatment, which can be used to guide future reporting.
Articolo in rivista - Articolo scientifico
autoimmune hepatitis; complete biochemical response; endpoints; insufficient response; intolerance; non-response; remission;
English
841
849
9
Pape, S., Snijders, R., Gevers, T., Chazouilleres, O., Dalekos, G., Hirschfield, G., et al. (2022). Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. JOURNAL OF HEPATOLOGY, 76(4 (April 2022)), 841-849 [10.1016/j.jhep.2021.12.041].
Pape, S; Snijders, R; Gevers, T; Chazouilleres, O; Dalekos, G; Hirschfield, G; Lenzi, M; Trauner, M; Manns, M; Vierling, J; Montano-Loza, A; Lohse, A; Schramm, C; Drenth, J; Heneghan, M; Almasio, P; Alvarez, F; Andrade, R; Arikan, C; Assis, D; Bardou-Jacquet, E; Biewenga, M; Cancado, E; Cazzagon, N; Chazouilleres, O; Colloredo, G; Cuarterolo, M; Dalekos, G; Debray, D; Robles-Diaz, M; Drenth, J; Dyson, J; Efe, C; Engel, B; Ferri, S; Fontana, R; Gatselis, N; Gerussi, A; Halilbasic, E; Halliday, N; Heneghan, M; Hirschfield, G; van Hoek, B; Horby Jorgensen, M; Indolfini, G; Iorio, R; Jeong, S; Jones, D; Kelly, D; Kerkar, N; Lacaille, F; Lammert, C; Leggett, B; Lenzi, M; Levy, C; Liberal, R; Lleo, A; Lohse, A; Ines Lopez, S; de Martin, E; Mclin, V; Mieli-Vergani, G; Milkiewicz, P; Mohan, N; Muratori, L; Nebbia, G; van Nieuwkerk, C; Oo, Y; Ortega, A; Pares, A; Pop, T; Pratt, D; Purnak, T; Ranucci, G; Rushbrook, S; Schramm, C; Stattermayer, A; Swain, M; Tanaka, A; Taubert, R; Terrabuio, D; Terziroli, B; Trauner, M; Valentino, P; van den Brand, F; Villamil, A; Wahlin, S; Ytting, H; Zachou, K; Zeniya, M
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/363235
Citazioni
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 5
Social impact